PedAM
Pediatric Disease Annotations & Medicines
| cystitis | ||||
| Disease ID | 1117 |
|---|---|
| Disease | cystitis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0030193 | pain | 17 C0021311 | infections | 6 C0020295 | hydronephrosis | 3 C0041956 | ureteral obstruction | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:27) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0010692 | acetylcysteine | D000111 | 616-91-1 | cystitis | MESH:D003556 | therapeutic | 1166056 | ||
| C0010692 | allopurinol | D000493 | 315-30-0 | cystitis | MESH:D003556 | marker/mechanism | 9158534 | ||
| C0010692 | amifostine | D004999 | 20537-88-6 | cystitis | MESH:D003556 | therapeutic | 10100560 | ||
| C0010692 | aminocaproic acid | D015119 | 60-32-2 | cystitis | MESH:D003556 | therapeutic | 1523745 | ||
| C0010692 | arsenic trioxide | C006632 | 1327-53-3 | cystitis | MESH:D003556 | marker/mechanism | 22099998 | ||
| C0010692 | busulfan | D002066 | 55-98-1 | cystitis | MESH:D003556 | marker/mechanism | 14625581 | ||
| C0010692 | carbenicillin | D002228 | 4697-36-3 | cystitis | MESH:D003556 | marker/mechanism | 6731385 | ||
| C0010692 | carboprost tromethamine | C062843 | 58551-69-2 | cystitis | MESH:D003556 | therapeutic | 1404668 | ||
| C0010692 | carmustine | D002330 | 154-93-8 | cystitis | MESH:D003556 | marker/mechanism | 6134004 | ||
| C0010692 | chlorambucil | D002699 | 305-03-3 | cystitis | MESH:D003556 | marker/mechanism | 7377464 | ||
| C0010692 | ciprofloxacin | D002939 | 85721-33-1 | cystitis | MESH:D003556 | therapeutic | 17478598 | ||
| C0010692 | cyclophosphamide | D003520 | 50-18-0 | cystitis | MESH:D003556 | marker/mechanism | 10100560 | ||
| C0010692 | cyclosporine | D016572 | 59865-13-3 | cystitis | MESH:D003556 | marker/mechanism | 12913734 | ||
| C0010692 | epirubicin | D015251 | 56420-45-2 | cystitis | MESH:D003556 | marker/mechanism | 7598036 | ||
| C0010692 | glutathione | D005978 | 70-18-8 | cystitis | MESH:D003556 | therapeutic | 16708234 | ||
| C0010692 | ifosfamide | D007069 | 3778-73-2 | cystitis | MESH:D003556 | marker/mechanism | 1100226 | ||
| C0010692 | indomethacin | D007213 | 53-86-1 | cystitis | MESH:D003556 | therapeutic | 15322343 | ||
| C0010692 | mesna | D015080 | 19767-45-4 | cystitis | MESH:D003556 | marker/mechanism | 12913734 | ||
| C0010692 | mesna | D015080 | 19767-45-4 | cystitis | MESH:D003556 | therapeutic | 10510257 | ||
| C0010692 | methotrexate | D008727 | 1959/5/2 | cystitis | MESH:D003556 | marker/mechanism | 12913734 | ||
| C0010692 | mitomycin | D016685 | 1950/7/7 | cystitis | MESH:D003556 | marker/mechanism | 10691844 | ||
| C0010692 | mitoxantrone | D008942 | 65271-80-9 | cystitis | MESH:D003556 | marker/mechanism | 8260250 | ||
| C0010692 | ribavirin | D012254 | 36791-04-5 | cystitis | MESH:D003556 | therapeutic | 12093990 | ||
| C0010692 | succimer | D004113 | 304-55-2 | cystitis | MESH:D003556 | therapeutic | 231445 | ||
| C0010692 | temozolomide | C047246 | 85622-93-1 | cystitis | MESH:D003556 | marker/mechanism | 12393995 | ||
| C0010692 | thiotepa | D013852 | 52-24-4 | cystitis | MESH:D003556 | marker/mechanism | 7495132 | ||
| C0010692 | vincristine | D014750 | - | cystitis | MESH:D003556 | marker/mechanism | 4551437 | ||
FDA approved drug and dosage information(Total Drugs:5) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003556 | busulfex | busulfan | 6MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
| MESH:D003556 | temodar | temozolomide | 5MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D003556 | temodar | temozolomide | 100MG/VIAL | POWDER;INTRAVENOUS | Prescription | None | Yes | Yes |
| MESH:D003556 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D003556 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003556 | 01/13/2003 | busulfex | busulfan | Part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases | The population pharmacokinetic estimates of busulfan for clearance and volume of distribution were determined in an open-label, uncontrolled PK study in 24 pediatric patients 5 months to 16 years who received busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases Suggested dosing regimen | Labeling | B | - | - | - | Orphan Medical | 12/3/2002 | FALSE' |
| MESH:D003556 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D003556 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D003556 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D003556 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |